PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026AIDS3 citationsOpen Access

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study

View Full Paper
NPNina PennetzdorferVNVidula NaikJMJairo M. Montezuma-Rusca

Key Points

  • The research aims to assess the resistance to bictegravir and lenacapavir in individuals undergoing treatment.
  • Conducted resistance analysis at baseline and week 48
  • Monitored participants receiving bictegravir and lenacapavir
  • Evaluated rates of viral suppression
  • High frequencies of baseline resistance observed
  • Substantial rates of viral suppression maintained through week 48
  • No on-treatment resistance to study drugs detected

Abstract

Despite high frequencies of baseline resistance, substantial rates of viral suppression were maintained through Week 48 and no on-treatment resistance to study drugs was detected. These findings support the development of once-daily BIC + LEN STR to improve and optimize treatment options in individuals on complex ART.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pennetzdorfer et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd73fdc3bde448919c15https://doi.org/10.1097/qad.0000000000004495
Ask AI
Helpful
Bookmark
Share
View Full Paper